Vitamin D receptor agonists as anti-inflammatory agents

Expert Review of Clinical Immunology

Volumn 3, Issue 4, 2007, Pages 477-489

  Adorini, Luciano ^a   Amuchastegui, Susana ^a   Corsiero, Elisa ^a   Laverny, Gilles ^a   Le Meur, Thomas ^a   Penna, Giuseppe ^a  

^a BioXell SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXY 16 DIENE 26,27 HEXAFLUORO 19 NORCOLECALCIFEROL; 19 NOR 14,20 BISEPI 23 YNE ALFACALCIDOL; 20 EPICALCITRIOL; 22 ENE 25 OXA VITAMIN D; ALFACALCIDOL; ANTIINFLAMMATORY AGENT; BXL 219; BXL 628; CYCLOSPORIN A; ELOCALCITOL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; LEXACALCITOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; SIMVASTATIN; TACROLIMUS; TX 527; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR AGONIST; ZK 156979;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CALCIUM INTAKE; CALCIUM METABOLISM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; DOSE RESPONSE; DRUG INDICATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENTERITIS; EVIDENCE BASED MEDICINE; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MITOSIS INHIBITION; MONOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOPOROSIS; PHOSPHATE METABOLISM; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN FUNCTION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

EID: 34447626100     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.4.477     Document Type: Review

References (99)

1. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. Faseb J. 15, 2579-2585 (2001).
2. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med. 8, 174-179. (2002).
3. Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu. Rev. Nutr. 23, 117-145 (2003).
4. Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res. 164, 29-42 (2003).
5. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell. Immunol. 233, 115-124 (2005).
6. Griffin MD, Kumar R. Multiple potential clinical benefits for 1α,25-dihydroxyvitamin D3 analogs in kidney transplant recipients. J. Steroid Biochem. Mol. Biol. 97, 213-218 (2005).
7. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 374, 334-338 (2000).
8. Adorini L, Giarratana N, Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin. Immunol. 16, 127-134 (2004).
9. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770-1773 (2006).
10. Wang TT, Nestel FP, Bourdeau V et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173, 2909-2912 (2004).
11. Cadranel J, Garabedian M, Milleron B, Guillozo H, Akoun G, Hance AJ. 1,25 (OH)"2D"3 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis. J. Clin. Invest. 85, 1588-1593 (1990).
12. Schauber J, Dorsdiner RA, Coda AB et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest. 117, 803-811 (2007).
13. Sigmundsdottir H, Pan J, Debes GF et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 8, 285-293 (2007).
14. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311, 17-18 (2006).
15. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275-306 (2005).
16. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 4, 24-34 (2004).
17. Adorini L, Penna G, Giarratana N et al. Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J. Steroid Biochem. Mol. Biol. 89-90, 437-441 (2004).
18. + regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 106, 3490-3497 (2005).
19. Martin E, O'Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 18, 155-167 (2003).
20. Rachez C, Freedman LP. Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. Gene 246, 9-21 (2000).
21. Gregod S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1α,25-dihydroxyvitamin D"3 and mycophenotate mofetil treatment mediate transplantation tolerance. J. Immunol. 167, 1945-1953 (2001).
22. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA 22, 22 (2001).
23. Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J. Cell. Biochem. 88, 227-233 (2003).
24. Penna G, Amuchastegui S, Giarratana N et al. 1,25-dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J. Immunol. 178, 145-153 (2007).
25. Nagpal S, Na S, Radinachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 26, 662-687 (2005).
26. +) T cells to enhance the development of Th2 cells. J. Immunol. 167, 4974-4980. (2001).
27. Mahon BD, Wittke A, Weaver V, Cantorna. MT. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J. Cell. Biochem. 89, 922-932 (2003).
28. Adorini L. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int. Immunopharmacol. 2, 1017-1028. (2002).
29. Penna G, Amuchastegui S, Cossetti C et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J. Immunol. 177, 8504-8511 (2006).
30. Steinman L. A brief history of T(H) 17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13, 139-145 (2007).
31. De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor κB. Oncogene 25, 6868-6886 (2006).
32. Li Q, Verma IM. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2, 725-734 (2002).
33. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 18, 2195-2224 (2004).
34. Dong X, Craig T, Xing N et al. Direct transcriptional regulation of RelB by 1α,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J. Biol. Chem. 278, 49378-49385 (2003).
35. Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and Type 1 diabetes development. J. Immunol. 173, 2280-2287 (2004).
36. Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A. Vitamin D decreases NFκB activity by increasing 1κBα levels. Nephrol. Dial. Transplant. 21, 889-897 (2006).
37. Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 66, 4516-4524 (2006).
38. Sun J, Kong J, Duan Y et al. Increased NF-κB activity in fibroblasts lacking the vitamin D receptor. Am. J. Physiol. Endocrinol. Metab. 291, E315-E322 (2006).
39. Hewison M, Freeman L, Hughes SV et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol. 170, 5382-5390 (2003).
40. Dong X, Lutz W, Schroeder TM et al. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc. Natl. Acad. Sci. USA 102, 16007-16012 (2005).
41. Penna G, Adorini L. 1α,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164, 2405-2411 (2000).
42. Xing N, ML LM, Bachman LA, McKean DJ, Kumar R, Griffin MD. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem. Biophys. Res. Commun. 297, 645-652 (2002).
43. Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J. Steroid Biochem. Mol. Biol. 103 (3-5), 558-562 (2006).
44. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from Type 2 diabetic patients have a pro-inflammatory profile 1,25-dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res. Clin. Pract. (2006).
45. 3 analog enhances regulatory T cells and arrests autoimmune diabetes in NOD mice. Diabetes 51, 1367-1374 (2002).
46. D'Ambrosio D, Sinigaglia F, Adorini L. Special attractions for suppressor T cells. Trends Immunol. 24, 122-126 (2003).
47. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004).
48. + T-cells in B-cell non-Hodgkin lymphoma. Blood (2006).
49. +) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195, 603-616 (2002).
50. Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog. Biophys. Mol. Biol. 92, 65-79 (2006).
51. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin. Proc. 81, 353-373 (2006).
52. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol. 97, 93-101 (2005).
53. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog. Biophys. Mol. Biol. 92, 60-64 (2006).
54. Adorini L, Gregori S, Harrison LC. Understanding autoimmune diabetes: insights from mouse models. Trends Mol. Med. 8, 31-38. (2002).
55. Adorini L, Penna G, Giarratana N, Mariani R, Uskokovic M. Inhibition of Type 1 diabetes development by vitamin D receptor agonists. Curr. Med. Chem. 4, 645-651 (2005).
56. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832-2838 (2006).
57. Brown SJ. The role ofvitamin D in multiple sclerosis. Ann. Pharmacother. 40, 1158-1161 (2006).
58. Muthian G, Raikwar HP, Rajasingh J, Bright JJ. 1,25 dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNγ axis leading to Th1 response in experimental allergic encephalomyelitis. J. Neurosci. Res. 83, 1299-1309 (2006).
59. Spach KM, Nashold FE, Dittel BN, Hayes CE. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J. Immunol. 177, 6030-6037 (2006).
60. Dresner-Pollak R, Ackerman Z, Eliakim R, Karban A, Chowers Y, Fidder HH. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet. Test. 8, 417-420 (2004).
61. Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm. Bowel Dis. 12, 1162-1174 (2006).
62. Neurath MF. IL-23: a master regulator in Crohn disease. Nat. Med. 13, 26-28 (2007).
63. Froicu M, Zhu Y, Cantorna MT. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology 117, 310-318 (2006).
64. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 8, 5 (2007).
65. Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1α,25-dihydroxyvitamin D3 target the TNF-α pathway to suppress experimental inflammatory bowel disease. Eur. J. Immunol. 35, 217-224 (2005).
66. Daniel C, Radeke HH, Sartory NA et al. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J. Pharmacol. Exp. Ther. 319, 622-631 (2006).
67. Stio M, Martinesi M, Bruni S et al. The Vitamin D analogue TX 527 blocks NF-κB activation in peripheral blood mononuclear cells of patients with Crohn's disease. J. Steroid Biochem. Mol. Biol. 103, 51-60 (2007).
68. Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Epidemiology of prostatitis: new evidence for a world-wide problem. World J. Urol. 21, 70-74 (2003).
69. Pontari MA, Ruggieri MR. Mechanisms in prostatitis/dironic pelvic pain syndrome. J. Urol. 172, 839-845 (2004).
70. Crescioli C, Ferruzzi P, Caporali A et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol. 150, 591-603 (2004).
71. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr. Opin. Urol. 16, 25-29 (2006).
72. Tinker AC, Wallace AV. Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases? Curr. Top. Med. Chem. 6, 77-92 (2006).
73. Krishnan AV, Moreno J, Norm L et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem. Mol. Biol. (2007).
74. Colli E, Rigatti P, Montorsi F et al. BXCL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur. Urol. 49, 82-86 (2006).
75. Adorini L. 1,25-dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr. Opin. Investig. Drugs. 3, 1458-1463 (2002).
76. Becker BN, Hullett DA, O'Herrin JK, Malin G, Sollinger HW, DeLuca H. Vitamin D as immunomodulatory therapy for kidney transplantation. Transplantation 74, 1204-1206 (2002).
77. Mathieu C, Jafari M. Immunomodulation by 1,25-dihydroxyvitamin D3: therapeutic implications in hemodialysis and renal transplantation. Clin. Nephrol. 66, 275-283 (2006).
78. van Etten E, Branisteanu DD, Verstuyf A, Waer M, Bouillon R, Mathieu C. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immumosuppressants. Transplantation 69, 1932-1942. (2000).
79. Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C. A combination of KH1060, a vitamin D(3) analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplant. Proc. 33, 2365. (2001).
80. Raisanen-Sokolowski AK, Pakkala IS, Samila SP, Binderup L, Hayry PJ, Pakkala ST. A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation 63, 936-941 (1997).
81. Stammberger U, Kubisa B, Gugger M et al. Strong additive effect of 1,25-dihydroxycholecalciferol and cyclosporine A but not tacrolimus in rat lung allotransplantation. Eur. J. Cardiothorac. Surg. 24, 196-200; discussion 200 (2003).
82. Vierboom M, Johnsson C, t Hart B, Jonker M. Monotherapy with the vitamin D analogue MC1288 does not result in prolonged kidney allograft survival in rhesus monkeys. Tanspl. Int. 19, 396-403 (2006).
83. Amuchastegui S, Daniel KC, Adorini L. Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist. Transplantation 80, 81-87 (2005).
84. Adorini L, Amuchastegui S, Daniel KC. Prevention of chronic allograft rejection by Vitamin D receptor agonists. Immunol. Lett. 100, 34-41 (2005).
85. Campbell MJ, Adorini L. The vitamin D receptor as a therapeutic target. Expert Opin. Ther. Targets 10, 735-748 (2006).
86. Charakida A, Dadzie O, Teixeira F, Charakida M, Evangelou G, Chu AC. Calcipotriol/βmethasone dipropionate for the treatment of psoriasis. Expert Opin. Pharmacother. 7, 597-606 (2006).
87. Ma Y, Khalifa B, Yee YK et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J. Clin. Invest. 116, 892-904 (2006).
88. Peleg S, Ismail A, Uskokovic MR, Avnur Z. Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J. Cell. Biochem. 88, 267-273 (2003).
89. Peleg S, Uskokovic M, Ahene A, Vickery B, Avnur Z. Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology 143, 1625-1636 (2002).
90. Adorini L, Penna G, Amuchastegui S et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J. Steroid Biochem. Mol. Biol. 103, 689-693 (2007).
91. Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ. 1α,25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nudear-factor-κB-mediated interleukin-8 gene expression. Eur. J. Biochem. 250, 63-71 (1997).
92. Mora JR, Iwata M, Eksteen B et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 314, 1157-1160 (2006).
93. Mebius RE. Vitamins in control of lymphocyte migration. Nat. Immunol. 8, 229-230 (2007).
94. Carlberg C, Dunlop TW. An integrated biological approach to nuclear receptor signaling in physiological control and disease. Crit. Rev. Eukaryot. Gene Expr. 16, 1-22 (2006).
95. Xystrakis E, Kusumakar S, Boswell S et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J. Clin. Invest. 116, 146-155 (2006).
96. Grimes DS. Are statins analogues of vitamin D? Lancet 368, 83-86 (2006).
97. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6, 358-370 (2006).
98. Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363, 1607-1608 (2004).
99. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 68, 1973-1981 (2005).